NCT04531072View on ClinicalTrials.gov

Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 18, 2018

Primary Completion Date

May 15, 2019

Study Completion Date

August 15, 2019

Conditions
Drug Interaction
Interventions
DRUG

Artemether-lumefantrine

Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy

DRUG

Atazanavir-ritonavir 300/100 mg

Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy

Trial Locations (1)

001

Apin (Aids Prevention Initiatives in Nigeria) clinic, Lagos University Teaching Hospital, Surulere

All Listed Sponsors
collaborator

NIH Office of AIDS Research (OAR)

NIH

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Fogarty International Center of the National Institute of Health

NIH

NCT04531072 - Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine | Biotech Hunter | Biotech Hunter